130 related articles for article (PubMed ID: 21397718)
41. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
Furesz J
Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
[TBL] [Abstract][Full Text] [Related]
42. Seroprevalence of antibodies against the three serotypes of poliovirus and IPV vaccine response in adult solid organ transplant candidates.
Brandão LGP; Santoro-Lopes G; Oliveira SS; da Silva EE; do Brasil PEAA
Vaccine; 2018 Jul; 36(31):4681-4686. PubMed ID: 29937244
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test.
Arita M; Iwai-Itamochi M
Sci Rep; 2019 Aug; 9(1):11970. PubMed ID: 31427704
[TBL] [Abstract][Full Text] [Related]
44. Repertoire of antibodies against type 1 poliovirus in human sera.
Rezapkin G; Neverov A; Cherkasova E; Vidor E; Sarafanov A; Kouiavskaia D; Dragunsky E; Chumakov K
J Virol Methods; 2010 Nov; 169(2):322-31. PubMed ID: 20691212
[TBL] [Abstract][Full Text] [Related]
45. Mapping of the epitopes of poliovirus type 2 in complex with antibodies.
Bannwarth L; Girerd-Chambaz Y; Arteni A; Guigner JM; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Oct; 67(2 Pt B):233-9. PubMed ID: 26059753
[TBL] [Abstract][Full Text] [Related]
46. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
47. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
Cáceres VM; Sutter RW
Clin Infect Dis; 2001 Aug; 33(4):531-41. PubMed ID: 11462191
[TBL] [Abstract][Full Text] [Related]
48. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.
Andreasen LV; Hansen LB; Andersen P; Agger EM; Dietrich J
Vaccine; 2015 Apr; 33(15):1873-9. PubMed ID: 25698487
[TBL] [Abstract][Full Text] [Related]
49. Immunochemical and biophysical characterization of inactivated Sabin poliovirus products: Insights into rapid quality assessment tools.
Westdijk J; Kogelman A; van der Put R; Eksteen Z; Suarez D; Kersten GFA; Metz B; Danial M
J Pharm Sci; 2022 Apr; 111(4):1058-1069. PubMed ID: 35114211
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
[TBL] [Abstract][Full Text] [Related]
51. Potency test of killed polio vaccines. Statistical analysis of test on chicken and preliminary results in combination with ELISA D-antigen determinations.
Larbaigt G; Moulin J; Souvras M; Gibelin N; Beranger G
Dev Biol Stand; 1981; 47():113-8. PubMed ID: 6262141
[TBL] [Abstract][Full Text] [Related]
52. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
53. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
55. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses.
Liu S; Lu W; Ma S; Guo H; Zhang Z; Li X
J Virol Methods; 2022 Feb; 300():114376. PubMed ID: 34826519
[TBL] [Abstract][Full Text] [Related]
58. Lack of adjuvant effect of the pertussis component on IPV DTP-polio vaccine in children.
Cadoz M; Montagnon B; Yvonnet B; Xueref C; Vincent-Falquet JC; Bandet R; Gibelin N
Dev Biol Stand; 1986; 65():153-8. PubMed ID: 2881819
[TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
Meriste S; Lutsar I; Tamm E; Willems P
Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
[TBL] [Abstract][Full Text] [Related]
60. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
